Trusted by several of the most esteemed organisations.
Kyberlife is also backed by top industry leaders and specialists in their field. As a global, open science marketplace, Kyberlife streamlines individual medical product catalogues into a diverse marketplace that would play host to authenticated products and services.
As leaders in their fields, our valued investors resonate well with Kyberlife’s story, mission and vision, which is why Kyberlife aims to stay true to our core and deliver what we promise.
Associate Professor Jeremy Lim (MD,MPH)
Investor
Dr Lim is currently the CEO of a microbiome company, AMiLi and advises senior officials at public sector agencies. He has extensive experience consulting and advising multinational private and NGO clients on national and regional strategies for go-to-market plans and implementation, government engagement and public-private partnerships. Dr. Jeremy holds appointments at (Saw Swee Hock School of Public Health, and Duke-NUS medical school).
Dr Jeremy also served as a partner in Oliver Wyman's Health and Life-Science practice and was the CEO of Fortis Colorectal Hospital. He has worked in senior executive roles in both public and private sectors, including time spent as a senior official in the Ministry of Health where he was also involved in a number of ‘Whole of Government’ initiatives. Dr. Jeremy chairs the steering committee of NIHA (NUS Initiative to Improve Health in Asia), and sits on the Behavioral Sciences Institute SMU, Centre for Health Informatics (NUS) and Next Age Institute (NUS) advisory boards.
He also contributes as immediate past President of the Fulbright Association and convener for the Johns Hopkins Bloomberg School of Public Health Singapore alumni. Dr. Jeremy enjoys serving in the NGO sector, the medical advisory committee of Dover Park Hospice and regionally is a Member of the ‘Save the Children’ Asia Corporate Advisory Council. He is also a volunteer physician with HealthServe.
Bernd Lepper
Investor
With over 25 years of professional sales, marketing, logistics and general management experience, Mr. Lepper is the Founder and CEO of Intega Health. Prior to Intega, he held multiple senior executive positions in DKSH (DiethelmKellerSiberHegner) with the last role held as the Regional Vice President of Healthcare.
He was responsible for leading the Healthcare organizations in SEA to Implement Market Expansion Services and attracting >200 Healthcare companies as new business partners for Market Entry; with coverage of the Pharmaceutical, OTC/Consumer Health, Medical Devices & Supplies, Dental, Ophthalmology and Companion Animal Health segments. Mr Lepper also has a track record in emerging pharmaceutical markets in Russia and SEA where he was the Managing Director of Sanofi-Aventis Indonesia, CFO of Aventis Pharma Thailand and Area Manager of the Eastern Europe Pharma Division of Hoechst AG.
Dr Christopher Ting
Investor
Dr Ting is currently serving as the Group CEO & Founder of Pathology Asia Holdings and Group CEO of INNOQUEST, South East Asia's largest laboratory network. He was previously responsible for heading Healthscope’s pathology interest in South East Asia. During his 6 years tenure, he implemented a number of quality and strategic initiatives which repositioned the businesses and allowed them to hold market leadership positions in their respective countries at the time of his departure.
Dr. Ting also brings unique insights into the healthcare scene in Singapore and Malaysia. He has worked at the Biomedical Sciences Group of the EDB Singapore, and has been a lead participant in the healthcare sector within Malaysia’s Economic Transformation Programme (ETP). He is the founder and first CEO of Quantum Diagnostics (Malaysia), Co- founder of Biomark (Singapore) and the CEO of Innovative Diagnostics (Singapore and HK). He has served as CEO of Timberland Medical Center (Malaysia).
Associate Professor Ong Eng Hui David (MD)
Investor
Dr David Ong is a gastroenterologist at Mount Elizabeth Hospital experienced in treating and managing conditions of the stomach, bowel and liver. Prior to Mt. E, Dr Ong was the head of gastroenterology and hepatology at the National University Hospital (NUH) and remains a visiting senior consultant.
Whilst at NUH, he held the positions of divisional director of clinical services, director of risk and values at the NUH cluster, and associate chairman of the medical board (medicolegal risk). He also holds an adjunct associate professorship at NUS's department of medicine and is also an advisor and chair of the nomination committee of the international council.
Dr Ong serves as the incoming president of the Gastroenterology Society of Singapore and the honorary secretary of the Chapter of Gastroenterology, Academy of Medicine. In addition, he has served as a member of the Singapore Medical Council Complaints Panel since 2016. In addition, he has served on multiple advisory boards of pharmaceutical companies, advising them on new treatments and advances in the field.
Maarten Kelder
Investor
Mr Kelder has more than 20 years of experience as a seasoned senior executive. He was the former Executive Vice-President of Stretegy and Corporate develoment for Zuellig Pharma and worked alongside Zuellig Pharma’s CEO to set and drive the company’s growth strategy and reputation with corporate stakeholders. Mr Kelder also lead Zuellig Pharma’s solutions businesses, spearheading the growth of its digital, data analytics, channel and patient care operations.
Prior to Zuellig Pharma, Maarten was the lead partner at Monitor Deloitte in Asia where he was particularly focused on corporate and business unit strategy; growth and innovation strategy; portfolio strategy and restructuring; partnering and M&A strategy; and organizational capability development. Maarten graduated with a BSC and MSC degrees from the University of Technology in Delft, Holland. He also holds an MBA from Tuck School of Business at Dartmouth College in the USA.
Rebecca Ng
Investor
Ms Ng is a senior executive for business development and operations. She is the current COO of Intega Health and has over 20 years of experience in elements such as market entry, expansion and supply chain. Prior to Intega, she was the ASEAN Supply chain director of Smith & Newphew and the Head of Operations (SEA) of Synthes.
Shaun Chua
Investor
Mr Chua is in business development at Mighty Jaxx. He has a professional background is in fullstack web development and product management, and I previously studied mathematics at NYU. He also finds game changing companies with 8 Mercatus and angel invest in his own capacity.
Sven Henrichwark
Mr Henrichwark leads SPRIM Ventures initiatives in Medtech. Sven has 20 years of operational leadership experience in the biotech, life science and medical technology industries with a successful track record as COO, CMO and GM of businesses at $1B/>1000FTE level and as a CEO at the $50-100M level. With over 10 years experience working in the US, Europe and Asia respectively, Sven has a global perspective and is passionate about bringing people and ideas together to build great businesses and teams.
Investor
Prior to SPRIM, he served as the executive vice president of APAC for AVANTOR/VWR, one of the largest laboratory product distributors internationally. Prior to joining VWR, Sven was the CEO of Echosens, Global Commercial GM of GE Life Sciences Bioprocess, Service GM and COO of GE Healthcare in Asia Pacific and the CMO of GE Life Sciences. In the earlier part of his career, Sven worked for the Monitor Group in LA and Paris and as a product manager for Incyte Genomics in the Bay Area.